Escape mechanisms in tumor immunity: A year 2000 update

Critical Reviews in Oncogenesis

Volumn 11, Issue 2, 2000, Pages 97-133

  Pawelec, G ^a   Heinzel, S ^a   Kiessling, R ^a   Muller, L ^a   Ouyang, Q ^a   Zeuthen, J ^a  

^a Section for Transplantation Immunology and Immunohaematology   (Germany)

Author keywords

Escape; Immunosurveillance; T cell mediated immunity; Tumor antigen; Tumor rejection

Indexed keywords

CHEMOKINE; CYTOKINE; HLA ANTIGEN; INTERLEUKIN 10; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; CELLULAR IMMUNITY; CLONAL ANERGY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR REJECTION;

ANIMAL; ANTIGENS, NEOPLASM; CLONAL ANERGY; CLONAL DELETION; DENDRITIC CELLS; HLA ANTIGENS; HUMAN; IMMUNIZATION; INTERLEUKIN-10; SIGNAL TRANSDUCTION; SUPPORT, NON-U.S. GOV'T; TUMOR ESCAPE;

EID: 0033833503     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (381)

1. Suppressive effect on lymphoproliferation in vitro by soluble annexin II released from isolated placental membranes
2. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2
3. Expression of MUC1 mucin on activated human T cells: Implications for a role of MUC1 in normal immune regulation
4. The biological role of mucins in cellular interactions and immune regulation: Prospects for cancer immunotherapy
5. CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs
6. Fas transduces activation signals in normal human T-lymphocytes
7. Human melanoma cell line M14 secretes a functional interleukin-2
8. Interferon-gamma reduces tumor-induced macrophage-mediated suppression: Role of prostaglandin-E2 and tumor necrosis factor-alpha
9. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E(2)
10. Induction of macrophage suppressor activity by fibrosarcoma-derived transforming growth factor-beta 1: Contrasting effects on resting and activated macrophages
11. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells
12. Serum interleukin-10 levels in patients affected with multiple myeloma: Correlation with the monoclonal component and disease progression
13. Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course
14. Beta(1)-Integrins on melanoma clones regulate the interaction with autologous cytolytic T-cell clones
15. T-cell-receptor engagement and tumor ICAM-1 up-regulation are required to by-pass low susceptibility of melanoma cells to autologous CTL-mediated lysis
16. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions
17. B7-1 expression by a non-antigen presenting cell-derived tumor
18. T cell tolerance and activation to a transgene-encoded tumor antigen
19. Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex
20. Crippling of CD3-zeta ITAMs does not impair T cell receptor signaling
21. Type 1 versus type 2 cytokine release by V beta T cell subpopulations determines in vivo anti-tumor reactivity -IL-10 mediates a suppressive role
22. Quantitative analysis of Th1, Th2 and TGF-beta 1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients
23. The inducible transcription activator NF-kappa B: Regulation by distinct protein subunits
24. The cytokine microenvironment of human colon carcinoma-lymphocyte expression of tumor necrosis factor-alpha and interleukin-4 predicts improved survival
25. CD95 (FAS/APO-1) antigen is a new prognostic marker of blast cells of acute lymphoblastic leukaemia patients
26. IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops
27. Lesion-specific activation of cloned human tumor-infiltrating lymphocytes by autologous tumor cells - Induction of proliferation and cytokine production
28. Soluble intercellular adhesion molecule-I inhibits MHC-restricted specific T-cell tumor interaction
29. + melanoma
30. Maintenance of clonal energy by endogenously produced IL-10
31. T cell clonality in immune responses
32. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas
33. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients
34. Mutations of the beta(2)-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides
35. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
36. IL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancer
37. Reversal of in vitro T-cell clonal anergy by IL-2 stimulation
38. Activation of CD40 favors the growth and vascularization of Kaposi's Sarcoma
39. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine
40. Prevention of T cell anergy by signaling through the gamma(c) chain of the IL-2 receptor
41. No evidence for MUC 1-induced apoptosis
42. Altered CD40 ligand induction in tolerant T lymphocytes
43. IL-2 treatment of B16F10 melanoma cells stimulates metastatic colonization in the liver
44. + T-cells responding to antigen presentation by melanoma cells
45. Immune surveillance in colorectal carcinoma
46. Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies
47. Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: A mechanism of tumor immune escape in leukemia patients
48. High frequency of altered HLA class I phenotypes in invasive breast carcinomas
49. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia
50. Recognition of autologous dendritic cells by human NK cells
51. T-cell receptor xi-chain expression on tumor-infiltrating lymphocytes from renal cell carcinoma
52. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen
53. Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T-cell activation
54. T cell-tumor cell: A fatal interaction?
55. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation
56. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats
57. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer
58. Alteration of signal-transducing molecules in tumor-infiltrating lymphocytes and peripheral blood T lymphocytes from human colorectal carcinoma patients
59. Functional interleukin-2 receptors on intestinal epithelial cells
60. Intercellular adhesion molecule-1 (ICAM-1) and granulocyte-macrophage colony stimulating factor (GM-CSF) co-expression in cutaneous malignant melanoma lesions
61. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: Implications for immunotherapy
62. Sequential development of structural and functional alterations in T cells from tumor-bearing mice
63. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: Lack of correlation with prognosis
64. Interleukin-2 receptors on squamous cell carcinomas of the head and neck - Characterization and functional role
65. Loss of transporter protein, encoded by the Tap-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas
66. Analysis of regulation of T-cell responses by soluble inhibitory factors from the sera of patients with Hodgkin's disease
67. Interleukin-4 protects chronic lymphocytic leukemic B-cells from death by apoptosis and upregulates Bcl-2 expression
68. A lack of evidence for down-modulation of CD3 zeta expression in colorectal carcinoma and pregnancy using multiple detection
69. A wide range of human cancers express interleukin-4 (IL4) receptors that can be targeted with chimeric toxin composed of IL-4 and pseudomonas exotoxin
70. In situ expression of B7 and CD28 receptor families in human malignant melanoma: Relevance for T-cell-mediated anti-tumor Immunity
71. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation
72. Dichotomy between naive and memory CD4(+) T cell responses to Fas engagement
73. Clonal anergy is induced in vitro by T-cell receptor occupancy in the absence of proliferation
74. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies
75. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions
76. Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: Correlation with diagnosis and disease status
77. An anergic, islet-infiltrating T-cell clone that suppresses murine diabetes secretes a factor that Blocks interleukin-2/interleukin-4-dependent proliferation
78. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
79. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors
80. Oncogene and cytokine expression of human colorectal tumors responding to immunotherapy
81. Evaluation of interleukin-6 in bronchoalveolar lavage fluid and serum of patients with lung cancer
82. Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens
83. Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10
84. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma
85. Interleukin-2 can prevent and reverse antigen-induced unresponsiveness in cloned human T lymphocytes
86. The decreased expression of CD3 xi chains in cancer patients is not reversed by IL-2 administration
87. Staining of interleukin-10 predicts clinical outcome in patients with nasopharyngeal carcinoma
88. Loss of T-cell receptor zeta-chain and p56(lck) in T-cells infiltrating human renal cell carcinoma
89. In vitro analysis of the melanoma endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells
90. Increased interleukin-10 serum levels in patients with solid tumors
91. Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice
92. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T cells in angiogenesis
93. Dendritic cells in antitumor immune responses. 2. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors
94. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
95. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes
96. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors
97. Caspase-mediated degradation of T-cell receptor zeta-chain
98. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes
99. Higher frequency of selective losses of HLA-A and -B allospecificities in metastasis than in primary melanoma lesions
100. Alterations in NF kappa B/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy
101. Loss of Th1 DNA-binding pattern and alterations in signal transduction molecules in T cells of renal cell carcinoma patients
102. Low prevalence of selective human leukocyte antigen (HLA)-A and HLA-B epitope losses in early-passage tumor cell lines
103. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation
104. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells
105. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory
106. Dendritic cells hold promise for immunotherapy
107. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4
108. Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy
109. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer
110. The effect of oxidative stress on human lymphocyte cytotoxicity
111. Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: Correlation with histological expression of ICAM-1 and tumor stage
112. A CD4(+) T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
113. Effect of tumor growth factor-beta on NK receptor expression by allostimulated CD8(+) T lymphocytes
114. High frequency of cancer patients with abnormal assembly of the T cell receptor-CD3 complex in peripheral blood T lymphocytes
115. Altered immune responses in interleukin 10 transgenic mice
116. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
117. On down-regulation of the immune response to metastatic malignant melanoma
118. Defensins are dominant HLA-DR-associated self peptides from CD34-peripheral blood mononuclear cells of different tumor patients (plasmacytoma, chronic myeloid leukemia)
119. Tumor progression by lung cancers growing in hosts of different immunocompetence
120. IL-2 triggers a tumor progression process in a melanoma cell line MELP, derived from a patient whose metastasis increased in size during IL-2/INF alpha biotherapy
121. Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-gamma production in mammary tumor-bearing mice
122. Anti-oncogenic and oncogenic potentials of interferon regulatory factor-1 and factor-2
123. Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer
124. Histaminergic receptors on NK cells
125. Expression of the intermediate affinity interleukin 2 receptor by a human solid tumor cell line: Evidence for functional activity
126. Beta 2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma
127. Loss of HLA haplotype in lung cancer cell lines: Implications for immunosurveillance of altered HLA classI/II phenotypes in lung cancer
128. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro
129. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: Frequency and distribution
130. Adenosine as a possible inhibitor of killer T-cell activation in the microenvironment of solid tumors
131. Interleukin-2 secretion by KHT sarcoma cells leads to lass of their vaccine potential
132. Human non-small cell lung cancer cells express a type 2 cytokine pattern
133. Regulation of tumor growth and metastasis by interleukin-10: The melanoma experience
134. A proinflammatory cytokine inhibits p53 tumor suppressor activity
135. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation
136. + T cells in the antitumor immune response
137. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
138. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor
139. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor
140. Primed T cells are more resistant to Fas-mediated activation-induced cell death than naive T cells
141. Stimulation of CD40 in human bladder carcinoma cells inhibits anti-Fas/APO-1 (CD95)-induced apoptosis
142. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8(+) cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo
143. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma
144. The role of cell division in the induction of clonal anergy
145. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors
146. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines
147. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis
148. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma - Association with disease progression
149. + lymphocytes-T
150. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction
151. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy
152. Characterization of autologous tumor-specific T-helper 2 cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma
153. IL-10 production in cutaneous basal and squamous cell carcinomas - A mechanism for evading the local T cell immune response
154. Modulation of CD4 cell cytokine production by colon cancer-associated mucin
155. Suppression of NF-kappaB activation in normal T cells by supernatant fluid from human renal cell carcinomas
156. Modulation of intercellular adhesion molecule-1 expression on human melanocytes and melanoma cells - Evidence for a regulatory role of IL-6, IL-7, TNFbeta, and UVB light
157. Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression
158. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes
159. Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes
160. Malignant neoplasms in long-term survivors of bone marrow transplantation
161. Decreased expression of signal-transducing zeta chain on peripheral T cells and NK cells in patients with cervical cancer
162. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell and natural killer cell-mediated cytotoxicity
163. Differences in the recognition of tumor-specific CD8(+) T cells derived from solid tumor, metastatic lymph nodes and ascites in patients with gastric cancer
164. Mechanisms of escape from CD8(+) T-cell clones specific for the HER-2/neu proto-oncogene expressed in ovarian carcinomas: Related and unrelated to decreased MHC class 1 expression
165. Human leukocyte antigen class I gene mutations in cervical cancer
166. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer
167. Characterization of tumor-infiltrating T lymphocytes in B-cell lymphomas of mucosa-associated lymphoid tissue
168. Expression of costimulatory molecules, B7-1 and B7-2 on human gastric carcinoma
169. Elevated plasma levels of transforming growth factor (TGF)-beta 1 and TGF-beta 2 in patients with disseminated malignant melanoma
170. Expression of interleukin 10 in human melanoma
171. Relationship between Fas-ligand expression on carcinoma cell and cytotoxic T-lymphocyte response in lymphoepithelioma-like cancer of the stomach
172. Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma - A potential mechanism for high tumor aggressiveness
173. T lymphocytes infiltrating sites of tumor rejection and progression display identical V beta usage but different cytotoxic activities
174. Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules
175. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma
176. Inhibitory MHC class I receptors on NK cells and T cells
177. Clonal deletion of thymocytes as a tumor escape mechanism
178. Enhancement of antitumor immunity by CTLA-4 blockade
179. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination
180. T helper 2-dominant antilymphoma immune response is associated with fatal outcome
181. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
182. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes
183. LFA-3 co-stimulates cytokine secretion by cytotoxic T lymphocytes by providing a TCR-independent activation signal
184. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection
185. Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma
186. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte
187. T cells from late tumor-bearing mice express normal levels of p56(lck), p59(fyn), ZAP-70, and CD3 zeta despite suppressed cytolytic activity
188. T cells from renal carcinoma patients show an abnormal pattern of kappa B-specific DNA-binding activity: A preliminary analysis
189. Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis
190. Impaired activation of NF kappa B in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, I Kappa B alpha
191. Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus - Deficient expression of the T cell receptor zeta chain
192. Regulation of the NF kappa B/rel transcriptional and I kappa B inhibitor system
193. Induction of T(h)2 cell differentiation in the primary immune response: Dendritic cells isolated from adherent cell culture treated with IL-10 prime naive CD4(+) T cells to secrete IL-4
194. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells
195. Anergic T cells as suppressor cells in vitro
196. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas
197. Human leukocyte antigen class I expression on squamous cell carcinoma cells regulates natural killer cell activity
198. Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions
199. Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients
200. TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice
201. Tumor escape from immune recognition - Lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen
202. Does antibody-dependent epitope masking permit progressive tumor growth in the face of cell-mediated cytotoxicity?
203. The origin and function of tumor-associated macrophages
204. Lack of correlation between defective cell-mediated immunity and levels of secreted or circulating cytokines in a study of 90 cancer patients - Clinical study
205. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines
206. Correlation between disease activity and T-cell CD3 zeta chain expression in a B-cell lymphoma
207. Dysregulated Fas and bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients
208. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression
209. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: Correlation with the stage of the disease
210. Decreased expression of signal-transducing CD3 zeta chains in T cells from the joints and peripheral blood of rheumatoid arthritis patients
211. A model for CD8(+) CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL
212. Defective TCR-mediated signaling in synovial T cells in rheumatoid arthritis
213. In vivo effects of hIL-10 on the growth of various tumors
214. Tumor gangliosides inhibit the tumor-specific immune response
215. Interleukin 2 receptor expression and interleukin 2 localisation in human solid tumor cells in situ and in vitro: Evidence for a direct role in the regulation of tumor cell proliferation
216. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein
217. Augmentation of an antitumor CTL response in vivo by inhibition of suppressor macrophage nitric oxide
218. Renal cell carcinoma induces interleukin 10 and prostaglandin E-2 production by monocytes
219. + TH0 cell clones
220. Frequent loss of heterozygosity on chromosome 6p in uveal melanoma
221. +) T cells
222. Alterations in signal transduction molecules in lymphocytes-T from tumor-bearing mice
223. Receptors for HLA class-I molecules in human natural killer cells
224. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions
225. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors
226. Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy?
227. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy
228. T cell receptor zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma
229. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: How do hepatoma cells escape from the host immune surveillance in vivo?
230. Decreased expression of the signal-transducing zeta-chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma
231. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma
232. Immune pathogenesis of hepatocellular carcinoma
233. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1
234. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells
235. Human lung carcinomas express Fas ligand
236. PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCR zeta expression but are functionally impaired
237. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma
238. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo
239. C-type lectin-like receptors in peptide-specific HLA class I-restricted cytotoxic T lymphocytes: Differential expression and modulation of effector functions in clones sharing identical TCR structure and epitope specificity
240. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma
241. Expression of fas (CD95/APO-1) ligand by human breast cancers: Significance for tumor immune privilege
242. Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA
243. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) mono-clonal antibody
244. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses
245. Fas and fas ligand interactions suppress melanoma lung metastasis
246. The addition of interleukin-2 to cyclophosphamide therapy can facilitate tumor growth of B16 melanoma
247. Expression of cell adhesion molecules in human melanoma cell lines and their role in cytotoxicity mediated by tumor-infiltrating lymphocytes
248. HLA-G expression in melanoma: A way for tumor cells to escape from immunosurveillance
249. Lack of evidence for an immunosuppressive role for MUC1
250. Immunosenescence: Ageing of the immune system
251. Interleukin 10 is a human T cell growth factor in vitro
252. Escape from host-antitumor immunity
253. T cell immunosenescence in vitro and in vivo
254. T cells and ageing
255. IFN-alpha regulates IL-10 production by CML cells in vitro
256. Tumor escape from the immune response: The last hurdle for successful immunotherapy of cancer?
257. Inhibition of tumor growth by elimination of granulocytes
258. The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles
259. Monocyte chemoattractant protein inhibits the generation of tumor-reactive T cells
260. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: A potential pathologic role
261. Generation of primary peptide-specific CD8(+) cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells
262. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1
263. Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines - Analysis of a single institution study on 181 patients
264. Selective expression of interleukin-10, interferon-gamma, and granulocyte macrophage colony-stimulating factor in ovarian cancer biopsies
265. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
266. Stimulatory effects of immune reactions upon the growths of untransplanted tumors
267. On the probability of effective anticancer vaccines
268. Expression of high-affinity IL-4 receptors on murine tumor infiltrating lymphocytes and their up-regulation by IL-2
269. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells
270. B cells inhibit induction of T cell-dependent tumor immunity
271. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma
272. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells - Implications for altered expression of T cell receptor in tumor-associated lymphocytes
273. Failure of carcinogen-altered dendritic cells to initiate T cell proliferation is associated with reduced IL-1 beta secretion
274. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma
275. The role of endogenous interleukin-2 in proliferation of human carcinoma cell lines
276. T cell immunosenescence and its clinical relevance in man
277. T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28
278. + T-cells against the wild-type tumor-correlation with antigen presentation capability
279. Identification of human cancers deficient in antigen processing
280. Interleukin-10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration
281. Immune selection after antigen-specific immunotherapy of melanoma
282. Human melanoma-reactive CD4(+) and CD8(+) CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing
283. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes
284. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer
285. Downregulation of lymphocyte mitogenesis by breast cancer-associated p43
286. Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia
287. Role of natural killer cells in psychosocial stressor-induced changes in mouse mammary tumor growth
288. Differential function of CD80- and CD86-transfected human melanoma cells in the presence of IL-12 and IFN-gamma
289. Effect of catalase on the proliferation of human lymphocytes to phorbol myristate acetate
290. IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression
291. Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-I0
292. Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and plasma thrombomodulin levels in glioblastoma patients
293. The progressive differentiation of primed T cells is associated with an increasing susceptibility to apoptosis
294. Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors
295. Serum levels of intercellular adhesion molecule 1 (ICAM-1) in patients with colorectal cancer: Inhibitory effect on cytotoxicity
296. Molecular characterization of defective antigen processing in human prostate cancer
297. Tumor necrosis factor-alpha expression in human primary malignant melanoma and its relationship to tumor infiltration by CD3(+) cells
298. Interleukin-4 is effective in restoring cytotoxic T cell activity that declines during in vivo progression of a murine B lymphoma
299. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival
300. Analysis of the T cell response to tumor and viral peptide antigens by an IFN gamma-elispot assay
301. Interleukin-10 signaling blocks inhibitor of kappa B kinase activity and nuclear factor kappa B DNA binding
302. Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro
303. Expression and function of the peptide transporters in escape variants of human renal cell carcinomas
304. TAP off - Tumors on
305. Suppression of cytotoxic T lymphocyte activity by gamma/delta T cells in tumor-bearing mice
306. Tumor-specific cytotoxic T lymphocyte activity in Th2-type Sezary syndrome: Its enhancement by interferon-gamma (IFN-gamma) and IL-12 and fluctuations in association with disease activity
307. Depletion of IL-10-and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells
308. Antigenic cancer cells that escape immune destruction are stimulated by host cells
309. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function
310. Generation of antigen-specific cytotoxic T lymphocytes and regulation of cytokine production takes place in the absence of CD3 zeta
311. Induction of tumor immunity by removing CD25(+)CD4(+) T cells: A common basis between tumor immunity and autoimmunity
312. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells
313. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas
314. CTLA-4 blockade reverses CD8(+) T-cell tolerance to tumor by a CD4(+) T cell-and IL-2-dependent mechanism
315. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells
316. Conversion of tumor-specific CD4(+) T-cell tolerance to T-cell priming through in vivo ligation of CD40
317. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes
318. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
319. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells
320. Incidence of de novo breast cancer in women chronically immunosuppressed after organ transplantation
321. In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes
322. B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism
323. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway
324. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand
325. IL-10 inhibits apoptotic cell death in human T-cells starved of IL-2
326. Mucin core protein expression in extra-hepatic bile duct carcinoma is associated with metastases to the liver and poor prognosis
327. Epidermal cell presentation of tumor-associated antigens for induction of tolerance
328. Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: Relationship with TIL phenotype and function
329. Predominant expression of Fas (CD95) ligand in metastatic melanoma revealed by longitudinal analysis
330. Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma
331. Expression of the co-stimulatory molecule CD40 on melanoma cells
332. Tumor-infiltrating T lymphocytes from renal-cell carcinoma express B7-1 (CD80): T-cell expansion by T-T cell co-stimulation
333. Enhanced tumor outgrowth after peptide vaccination - Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors
334. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction
335. Immuno-selection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes: Possible mechanisms for immunotherapeutic failures
336. Nitric oxide up-regulates the expression of intercellular adhesion melecule-1 on cancer cells
337. IFN-gamma gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer
338. High levels of transforming growth factor beta 1 in patients with colorectal cancer: Association with disease progression
339. Administration of IL-12 induces a CD3(+) CD4(-)CD8(-)B220(+) lymphoid population capable of eliciting cytolysis against Fas-positive tumor cells
340. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis
341. Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappa B activation in T cells
342. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients
343. Human ex vivo carcinoma cells produce transforming growth factor beta and thereby can inhibit lymphocyte functions in vitro
344. Differential ability of T cell subsets to undergo activation-induced cell death
345. High incidence of interleukin-10 mRNA but not interleukin-2 mRNA detected in human breast tumors
346. Relative survival in elderly cancer patients in Europe
347. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance
348. T-cell activation by antigens on human melanoma cells - Co-stimulation by B7-1 is neither sufficient nor necessary to stimulate IL-2 secretion by melanoma-specific T cell clones in vitro
349. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions
350. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis
351. An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma
352. Immune response against human primary malignant melanoma: A distinct cytokine mRNA profile associated with spontaneous regression
353. Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back - Commentary
354. Limited T cell antigen receptor repertoire in tumor-infiltrating lymphocyte and inhibition of experimental lung metastasis of murine melanoma by anti-TCR antibody
355. Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29
356. Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by berrant pre-mRNA splicing in 624 MEL 28 melanoma cells
357. Receptors for interleukin-2 on human squamous cell carcinoma cell lines and tumor in situ
358. CD95-dependent T-cell killing by glioma cells expressing CD95 ligand: More on tumor immune escape, the CD95 counterattack, and the immune privilege of the brain
359. Restoration of MHC class I surface expression and endogenous antigen presentation by a molecular chaperone
360. +) cells can be overcome with vitamin D-3 treatment to diminish CD34(+) cell levels
361. B cell-mediated down-regulation of IFN-gamma and IL-12 production induced during antitumor immune responses in the tumor-bearing state
362. Lysis of human melanoma cells by autologous cytolytic T-cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens
363. +) T cells specific for transporter associated with antigen processing deficient cells
364. Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T cells or macrophages in the tumor-bearing state
365. Local Expression of Antiinflammatory Cytokines in Cancer
366. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation
367. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages
368. A fundamental difference in the capacity to induce proliferation of naive T cells between CD28 and other co-stimulatory molecules
369. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner
370. Expression of interleukin 2 receptors on human carcinoma cell lines and tumor growth inhibition by interleukin 2
371. Interleukin 2 restores CD3-zeta chain expression but fails to generate tumor-specific lytic activity in tumor-infiltrating lymphocytes derived from human colorectal hepatic metastases
372. Mechanisms of immune suppression in patients with head and neck cancer: Influence on the immune infiltrate of the cancer
373. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-1, HLA class-II and ICAM-1 molecules
374. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: Selective rescue by caspase inhibition
375. Alterations in T cell receptor and signal-transduction molecules in melanoma patients
376. Changes in signal transduction molecules in patients with lepromatous leprosy
377. Downregulation of TAP-1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10
378. Induction of CD4(+) T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta(1)
379. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma
380. Functional expression of TRAIL by lymphoid and myeloid tumor cells
381. Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: Lessons from recurrent tumors